National Research (NRC) Stock Forecast, Price & News

National Research's stock was trading at $37.30 at the start of the year. Since then, NRC stock has increased by 21.4% and is now trading at $45.29.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our NRC earnings forecast.

National Research Co. (NASDAQ:NRC) issued its quarterly earnings results on Tuesday, February, 11th. The company reported $0.34 EPS for the quarter. The business earned $32.62 million during the quarter. National Research had a net margin of 20.20% and a trailing twelve-month return on equity of 42.71%.

National Research announced a quarterly dividend on Thursday, May 25th. Shareholders of record on Friday, June 30th will be given a dividend of $0.12 per share on Friday, July 14th. This represents a $0.48 annualized dividend and a yield of 1.06%. The ex-dividend date of this dividend is Thursday, June 29th.
Read our dividend analysis for NRC.

ETFs with the largest weight of National Research (NASDAQ:NRC) stock in their portfolio include Royce Quant Small-Cap Quality Value ETF (SQLV), Hartford Multifactor Small Cap ETF (ROSC), SPDR S&P Health Care Services ETF (XHS), Timothy Plan US Small Cap Core ETF (TPSC), iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) and WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS).

National Research (NASDAQ:NRC) pays an annual dividend of $0.48 per share and currently has a dividend yield of 1.05%. The dividend payout ratio is 39.67%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for NRC.

85 employees have rated National Research Chief Executive Officer Michael D. Hays on Glassdoor.com. Michael D. Hays has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other National Research investors own include Altria Group (MO), Enterprise Products Partners (EPD), AbbVie (ABBV), Dominion Energy (D), Gilead Sciences (GILD), Pfizer (PFE), Toronto-Dominion Bank (TD), Verizon Communications (VZ), Wells Fargo & Company (WFC) and TD Ameritrade (AMTD).

National Research trades on the NASDAQ under the ticker symbol "NRC."

National Research's stock is owned by many different institutional and retail investors. Top institutional investors include Kayne Anderson Rudnick Investment Management LLC (13.05%), BlackRock Inc. (4.12%), Conestoga Capital Advisors LLC (2.98%), Dimensional Fund Advisors LP (2.56%), QV Investors Inc. (1.83%) and Renaissance Technologies LLC (1.49%). Insiders that own company stock include Amandla Mk Trust, Joann M Martin, John N Nunnelly, Jona S Raasch, Kevin R Karas and Steven D Jackson.
View institutional ownership trends.

Shares of NRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NRC stock can currently be purchased for approximately $45.29.

National Research (NASDAQ:NRC) has a market capitalization of $1.11 billion and generates $151.57 million in revenue each year. The company earns $31.80 million in net income (profit) each year or $1.21 on an earnings per share basis.

The company employs 511 workers across the globe.

National Research's mailing address is 1245 Q STREET, LINCOLN NE, 68508. The official website for the company is www.nrchealth.com. The company can be reached via phone at (402) 475-2525 or via fax at 402-475-9061.